Chronic Dosing with Metformin Plus Bosentan Decreases in Vitro Pulmonary Artery Contraction from Isolated Arteries in Adults with Pulmonary Hypertension

Overview

Journal J Cardiovasc Thorac Res

Specialty Cardiology & Vascular Diseases

Date 2019 Oct 4

PMID 31579458

Citations 5

Authors

Shutan Liao

Dongsheng Li

Zheng Hui

Craig S McLachlan

Yang Zhang

Affiliations

Soon will be listed here.

Abstract

Pulmonary arterial hypertension (PAH) specific drug therapy using bosentan has significantly improved quality of life and survival, although PAH is still an incurable disease. Recent studies suggest metformin may have additional treatment benefits in PAH. We therefore investigated in vitro pulmonary artery reactivity after combination therapy of bosentan and metformin in PAH patients as compared with bosentan monotherapy in a prospective, randomized study. Adult patients with PAH associated with congenital heart defects (PAH-CHD) were randomised to receive bosentan (initially at 62.5 mg twice daily for 4 weeks and then 125 mg twice daily) for 3 months with or without the combination treatment of metformin (500 mg twice daily). Vessel reactivity of isolated pulmonary arteries was examined using a wire myograph. Phenylephrine (PE)-induced contractions of arteries in patients received combination therapy were significantly attenuated at concentrations of 3 × 10 M, 10 M and 3 × 10 M, compared to those received bosentan monotherapy. After denudation, PE-induced contractions at concentrations of 3 × 10 M and 10 M were significantly decreased in the combination therapy group. AMP-activated protein kinase (AMPK) inhibitor compound C abrogated the inhibitory effects of metformin on PE-induced contractility. AMPK and eNOS phosphorylation in the pulmonary arteries of patients treated with combination therapy was increased compared to monotherapy ( < 0.05). Adding metformin to bosentan therapy in patients with PAH-CHD decreased pulmonary artery contraction induced by PE, which is possibly related to increased AMPK phosphorylation.

Citing Articles

The role and mechanism of AMPK in pulmonary hypertension.

Hou J, Nie Y, Wen Y, Hua S, Hou Y, He H Ther Adv Respir Dis. 2024; 18:17534666241271990.

PMID: 39136335 PMC: 11322949. DOI: 10.1177/17534666241271990.

Insights into Endothelin Receptors in Pulmonary Hypertension.

Liu R, Yuan T, Wang R, Gong D, Wang S, Du G Int J Mol Sci. 2023; 24(12).

PMID: 37373355 PMC: 10299084. DOI: 10.3390/ijms241210206.

Protective effects of metformin in various cardiovascular diseases: Clinical evidence and AMPK-dependent mechanisms.

Bu Y, Peng M, Tang X, Xu X, Wu Y, Chen A J Cell Mol Med. 2022; 26(19):4886-4903.

PMID: 36052760 PMC: 9549498. DOI: 10.1111/jcmm.17519.

Inhibitors of Mitochondrial Dynamics Mediated by Dynamin-Related Protein 1 in Pulmonary Arterial Hypertension.

Xiao F, Zhang R, Wang L Front Cell Dev Biol. 2022; 10:913904.

PMID: 35846374 PMC: 9280643. DOI: 10.3389/fcell.2022.913904.

AMPK and Pulmonary Hypertension: Crossroads Between Vasoconstriction and Vascular Remodeling.

Zhao Q, Song P, Zou M Front Cell Dev Biol. 2021; 9:691585.

PMID: 34169079 PMC: 8217619. DOI: 10.3389/fcell.2021.691585.

References

Hawley S, Davison M, Woods A, DAVIES S, Beri R, Carling D . Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem. 1996; 271(44):27879-87. DOI: 10.1074/jbc.271.44.27879. View

Song Y, Wu Y, Su X, Zhu Y, Liu L, Pan Y . Activation of AMPK inhibits PDGF-induced pulmonary arterial smooth muscle cells proliferation and its potential mechanisms. Pharmacol Res. 2016; 107:117-124. DOI: 10.1016/j.phrs.2016.03.010. View

van Riel A, Schuuring M, van Hessen I, Zwinderman A, Cozijnsen L, Reichert C . Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification. Int J Cardiol. 2014; 174(2):299-305. DOI: 10.1016/j.ijcard.2014.04.072. View

Tuder R . Pulmonary vascular remodeling in pulmonary hypertension. Cell Tissue Res. 2016; 367(3):643-649. PMC: 5408737. DOI: 10.1007/s00441-016-2539-y. View

Kemp K, Savale L, OCallaghan D, Jais X, Montani D, Humbert M . Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant. 2011; 31(2):150-8. DOI: 10.1016/j.healun.2011.11.002. View

Joya-Galeana J, Fernandez M, Cervera A, Reyna S, Ghosh S, Triplitt C . Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects. Diabetes Metab Res Rev. 2011; 27(4):373-82. PMC: 4416699. DOI: 10.1002/dmrr.1185. View

Abbasi F, Chu J, McLaughlin T, Lamendola C, Leary E, Reaven G . Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism. 2004; 53(2):159-64. DOI: 10.1016/j.metabol.2003.07.020. View

Salt I, Grahame Hardie D . AMP-Activated Protein Kinase: An Ubiquitous Signaling Pathway With Key Roles in the Cardiovascular System. Circ Res. 2017; 120(11):1825-1841. PMC: 5447810. DOI: 10.1161/CIRCRESAHA.117.309633. View

Sharma R, Bhalla R . Metformin attenuates agonist-stimulated calcium transients in vascular smooth muscle cells. Clin Exp Hypertens. 1995; 17(6):913-29. DOI: 10.3109/10641969509033643. View

10.

Hu Z, Xie B, Zhai X, Liu J, Gu J, Wang X . Midterm results of "treat and repair" for adults with non-restrictive ventricular septal defect and severe pulmonary hypertension. J Thorac Dis. 2015; 7(7):1165-73. PMC: 4522505. DOI: 10.3978/j.issn.2072-1439.2015.07.06. View

11.

Davis B, Xie Z, Viollet B, Zou M . Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes. 2006; 55(2):496-505. DOI: 10.2337/diabetes.55.02.06.db05-1064. View

12.

Low A, George S, Howard L, Bell N, Millar A, Tulloh R . Lung Function, Inflammation, and Endothelin-1 in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension. J Am Heart Assoc. 2018; 7(4). PMC: 5850183. DOI: 10.1161/JAHA.117.007249. View

13.

Cao X, Li H, Tao H, Wu N, Yu L, Zhang D . Metformin inhibits vascular calcification in female rat aortic smooth muscle cells via the AMPK-eNOS-NO pathway. Endocrinology. 2013; 154(10):3680-9. DOI: 10.1210/en.2013-1002. View

14.

Agard C, Rolli-Derkinderen M, Dumas-de-La-Roque E, Rio M, Sagan C, Savineau J . Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension. Br J Pharmacol. 2009; 158(5):1285-94. PMC: 2782337. DOI: 10.1111/j.1476-5381.2009.00445.x. View

15.

Bain J, Plater L, Elliott M, Shpiro N, Hastie C, McLauchlan H . The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007; 408(3):297-315. PMC: 2267365. DOI: 10.1042/BJ20070797. View

16.

Chen H, Li J, Yang O, Kong J, Lin G . Effect of metformin on insulin-resistant endothelial cell function. Oncol Lett. 2015; 9(3):1149-1153. PMC: 4314968. DOI: 10.3892/ol.2015.2883. View

17.

Dean A, Nilsen M, Loughlin L, Salt I, MacLean M . Metformin Reverses Development of Pulmonary Hypertension via Aromatase Inhibition. Hypertension. 2016; 68(2):446-54. DOI: 10.1161/HYPERTENSIONAHA.116.07353. View

18.

Grant P . Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab. 2003; 29(4 Pt 2):6S44-52. DOI: 10.1016/s1262-3636(03)72787-6. View

19.

Grahame Hardie D . AMPK: positive and negative regulation, and its role in whole-body energy homeostasis. Curr Opin Cell Biol. 2014; 33:1-7. DOI: 10.1016/j.ceb.2014.09.004. View

20.

Humbert M, Barst R, Robbins I, Channick R, Galie N, Boonstra A . Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004; 24(3):353-9. DOI: 10.1183/09031936.04.00028404. View